We were delighted to catch up with Mehdi Rashighi (University of Massachusetts Medical School, Boston, MA, USA) to discuss the use of JAK inhibitors in the treatment of vitiligo.
Questions
- What are the limitations of current therapeutic approaches for vitiligo? (0:26)
- What is the role of the JAK pathway in the pathogenesis of vitiligo? (0:56)
- What clinical evidence supports the use of JAK inhibitors in vitiligo? (1:51)
- What have been the long-term safety findings of clinical trials to date? (3:00)
- Which patients with vitiligo are likely to benefit most from JAK inhibitors and in whom are they contraindicated? (4:40)
Disclosures: In this interview, Mehdi Rashighi discusses unapproved uses of approved products. He was advised by Touch Medical Media to ensure that he disclosed any such references made to unlabelled or unapproved use. No endorsement by Touch Medical Media of any unapproved products or unapproved uses is either made or implied by the mention of these products.
Mehdi Rashighi is the Principal Investigator of studies sponsored by Target RWE and LEO Pharma. He is also Co-Investigator of studies sponsored by Pfizer, Sanofi, Incyte, and Dermavant and serves as an Editorial Board Member of FASEB, Frontiers in Immunology, and VisualDx.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the EADV 2020 Virtual Congress.
